<?xml version="1.0" encoding="UTF-8"?>
<p>Anti‐TNF agents have been shown to increase the risk of upper and lower respiratory tract infections, as well as serious and opportunistic pulmonary infections.
 <xref rid="apt15779-bib-0062" ref-type="ref">
  <sup>62</sup>
 </xref>, 
 <xref rid="apt15779-bib-0075" ref-type="ref">
  <sup>75</sup>
 </xref>, 
 <xref rid="apt15779-bib-0076" ref-type="ref">
  <sup>76</sup>
 </xref> Compared with anti‐TNF monotherapy, risk of serious infections increases with combination of anti‐TNF and an immunosuppressive agent or most significantly in combination with corticosteroids.
 <xref rid="apt15779-bib-0077" ref-type="ref">
  <sup>77</sup>
 </xref> In a study that did not separate mono—or combination—anti‐TNF therapies, the risk of pneumonia was only slightly increased in patients receiving a TNF antagonist (OR: 1.28, 95% CI [1.08‐1.52]).
 <xref rid="apt15779-bib-0062" ref-type="ref">
  <sup>62</sup>
 </xref>
</p>
